Pre-clinical experimentation and clinical research
Pre-clinical experimentation and clinical research
Contact
Arronax Nantes > Pre-clinical experimentation and clinical research > Our publications > Article

Preclinical experimentation and clinical research

  • Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice, Roncali L, Marionneau-Lambot S, Roy C, Eychenne R, Gouard S, Avril S, et al., eBioMedicine [Internet]. 1 July 2024, https://doi.org/10.1016/j.ebiom.2024.105202

  • Validation of the ΔSUVmax for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical study. Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bodéré F, Meignan M, Gat E, Le Gouill S, Casasnovas RO, Bodet-Milin C. J Nucl Med. 2023, 64: 1706-1711. https://doi.org/10.2967/jnumed.123.265871

  • Multiple myeloma mimicking metastatic skull base paraganglioma in [68 Ga]Ga-DOTATOC-PET/CT and 2-[18F]FDG-PET/CT imaging. Jamet B, Bodet-Milin C, Moreau P, Touzeau C, Kraeber-Bodéré F. Eur J Nucl Med Mol Imaging. 2023, 3792-3793. https://doi.org/10.1007/s00259-023-06322-0

  • New developments in myeloma treatment and response assessment. Kraeber-Bodéré F, Jamet B, Bezzi D, Zamagni E, Moreau P, Nanni C. J Nucl Med. 2023, 64: 1331-1343. https://doi.org/10.2967/jnumed.122.264972

  • PSMA is not specific to prostate cancer. Ah-Thiane L, Ferrer L, Rousseau C. J Nucl Med. 2023, 64: 1326. https://doi.org/10.2967/jnumed.123.265720

  • 2-[18F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma. Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bodéré F, Touzeau C. Clin Nucl Med. 2023, 48: e230-e231. https://doi.org/10.1097/rlu.0000000000004588

  • Radioimmunotherapy of non-Hodgkin B-cell Lymphoma: an update. Cicone F, Santo G, Bodet-Milin C, Cascini GL, Kraeber-Bodere F, Stokke C, Kolstad A. Semin Nucl Med. 2023, 53: 413-425. https://doi.org/10.1053/j.semnuclmed.2022.12.006

  • Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy. Metz R, Rauscher A, Vaugier L, Supiot S, Drouet F, Campion L, Rousseau C. Cancers. 2023, 15: 1898. https://doi.org/10.3390/cancers15061898

  • Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. Kraeber-Bodéré F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin M-D, Minnema MC, Jamet B, Bodet-Milin C, de Keizer B, Béné MC, Avet-Loiseau H, Sonneveld P, Pei L, Rigat F, de Boer C, Vermeulen J, Kampfenkel T, Lambert J, Moreau P. Haematologica. 2023, 108: 621-626.
    https://doi.org/10.3324/haematol.2021.280051

  • Clinical advances and perspectives in targeted radionuclide therapy. Lepareur N., Ramée B., Mougin-Degraef M., Bourgeois M. Pharmaceutics 2023; 15(6). https://doi.org/10.3390/pharmaceutics15061733

see more results